{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:19:08Z","timestamp":1790756348474,"version":"4.1.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T00:00:00Z","timestamp":1528243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10096-018-3289-4","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T02:23:28Z","timestamp":1528251808000},"page":"1817-1827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches"],"prefix":"10.1007","volume":"37","author":[{"given":"Sara A.","family":"Taleb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa A.","family":"Al Thani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Al Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-2788","authenticated-orcid":false,"given":"Hadi M.","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,6]]},"reference":[{"issue":"3","key":"3289_CR1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/ijms18030556","volume":"18","author":"E Rey-Jurado","year":"2017","unstructured":"Rey-Jurado E, Kalergis AM (2017) Immunological features of respiratory syncytial virus-caused pneumonia\u2014implications for vaccine design. Int J Mol Sci 18(3):556","journal-title":"Int J Mol Sci"},{"issue":"9725","key":"3289_CR2","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","volume":"375","author":"H Nair","year":"2010","unstructured":"Nair H et al (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375(9725):1545\u20131555","journal-title":"Lancet"},{"key":"3289_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.coviro.2017.03.012","volume":"23","author":"BS Graham","year":"2017","unstructured":"Graham BS (2017) Vaccine development for respiratory syncytial virus. Curr Opin Virol 23:107\u2013112","journal-title":"Curr Opin Virol"},{"issue":"13","key":"3289_CR4","doi-asserted-by":"publisher","first-page":"5965","DOI":"10.1128\/JVI.00235-16","volume":"90","author":"I Widjaja","year":"2016","unstructured":"Widjaja I et al (2016) Characterization of epitope-specific anti-respiratory syncytial virus (anti-RSV) antibody responses after natural infection and after vaccination with formalin-inactivated RSV. J Virol 90(13):5965\u20135977","journal-title":"J Virol"},{"key":"3289_CR5","unstructured":"Varga SM, Braciale TJ (2013) The adaptive immune response to respiratory syncytial virus. Curr Top Microbiol Immunol 372:155\u2013171"},{"issue":"10","key":"3289_CR6","first-page":"680","volume":"14","author":"RB Sawadkohi","year":"2012","unstructured":"Sawadkohi RB et al (2012) Prevalence of acute lower respiratory tract infections due to respiratory syncytial virus in Amirkola Children\u2019s Hospital, Northern Iran during March 2008\u2013March 2010. Iran Red Crescent Med J 14(10):680","journal-title":"Iran Red Crescent Med J"},{"key":"3289_CR7","doi-asserted-by":"crossref","unstructured":"Collins PL (1991) The molecular biology of human respiratory syncytial virus (RSV) of the genus pneumovirus. In: Kingsbury DW (eds) The paramyxoviruses. The viruses. Springer, Boston","DOI":"10.1007\/978-1-4615-3790-8_4"},{"issue":"13","key":"3289_CR8","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1073\/pnas.83.13.4594","volume":"83","author":"PL Collins","year":"1986","unstructured":"Collins PL et al (1986) Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order. Proc Natl Acad Sci 83(13):4594\u20134598","journal-title":"Proc Natl Acad Sci"},{"key":"3289_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.coi.2015.04.005","volume":"35","author":"BS Graham","year":"2015","unstructured":"Graham BS, Modjarrad K, McLellan JS (2015) Novel antigens for RSV vaccines. Curr Opin Immunol 35:30\u201338","journal-title":"Curr Opin Immunol"},{"key":"3289_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-3687-8","volume-title":"Human respiratory syncytial virus","author":"RA Tripp","year":"2016","unstructured":"Tripp RA, Jorquera PA (2016) Human respiratory syncytial virus. Springer, Berlin"},{"key":"3289_CR11","volume-title":"The paramyxoviruses","author":"DW Kingsbury","year":"2012","unstructured":"Kingsbury DW (2012) The paramyxoviruses. Springer Science & Business Media, Berlin"},{"issue":"20","key":"3289_CR12","doi-asserted-by":"publisher","first-page":"11899","DOI":"10.1128\/JVI.00839-14","volume":"88","author":"Y Li","year":"2014","unstructured":"Li Y et al (2014) Inhibition of the human respiratory syncytial virus small hydrophobic protein and structural variations in a bicelle environment. J Virol 88(20):11899\u201311914","journal-title":"J Virol"},{"key":"3289_CR13","doi-asserted-by":"crossref","unstructured":"Barik S (2013) Respiratory syncytial virus mechanisms to interfere with type 1 interferons. Curr Top Microbiol Immunol 372:173\u2013191","DOI":"10.1007\/978-3-642-38919-1_9"},{"key":"3289_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jviromet.2016.07.012","volume":"236","author":"V Chin","year":"2016","unstructured":"Chin V et al (2016) Design and validation of small interfering RNA on respiratory syncytial virus M2-2 gene: a potential approach in RNA interference on viral replication. J Virol Methods 236:117\u2013125","journal-title":"J Virol Methods"},{"issue":"2","key":"3289_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1086\/314876","volume":"180","author":"S Chamat","year":"1999","unstructured":"Chamat S et al (1999) Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus\u2014transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus. J Infect Dis 180(2):268\u2013277","journal-title":"J Infect Dis"},{"issue":"4","key":"3289_CR16","doi-asserted-by":"publisher","first-page":"e1005554","DOI":"10.1371\/journal.ppat.1005554","volume":"12","author":"S Fuentes","year":"2016","unstructured":"Fuentes S et al (2016) Antigenic fingerprinting following primary RSV infection in young children identifies novel antigenic sites and reveals unlinked evolution of human antibody repertoires to fusion and attachment glycoproteins. PLoS Pathog 12(4):e1005554","journal-title":"PLoS Pathog"},{"issue":"10","key":"3289_CR17","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1099\/0022-1317-66-10-2111","volume":"66","author":"MA Mufson","year":"1985","unstructured":"Mufson MA et al (1985) Two distinct subtypes of human respiratory syncytial virus. J Gen Virol 66(10):2111\u20132124","journal-title":"J Gen Virol"},{"issue":"9","key":"3289_CR18","doi-asserted-by":"publisher","first-page":"e74018","DOI":"10.1371\/journal.pone.0074018","volume":"8","author":"UB Aamir","year":"2013","unstructured":"Aamir UB et al (2013) Molecular characterization of circulating respiratory syncytial virus (RSV) genotypes in gilgit baltistan province of Pakistan during 2011-2012 winter season. PLoS One 8(9):e74018","journal-title":"PLoS One"},{"issue":"4","key":"3289_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/tropej\/fml002","volume":"52","author":"R Al-Toum","year":"2006","unstructured":"Al-Toum R, Bdour S, Ayyash H (2006) Epidemiology and clinical characteristics of respiratory syncytial virus infections in Jordan. J Trop Pediatr 52(4):282\u2013287","journal-title":"J Trop Pediatr"},{"key":"3289_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2147\/CEOR.S60710","volume":"6","author":"TL Turner","year":"2014","unstructured":"Turner TL et al (2014) Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res 6:217","journal-title":"Clinicoecon Outcomes Res"},{"issue":"6","key":"3289_CR21","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1542\/peds.2009-2345","volume":"124","author":"CoI Diseases","year":"2009","unstructured":"Diseases CoI (2009) Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 124(6):1694\u20131701","journal-title":"Pediatrics"},{"issue":"9181","key":"3289_CR22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0140-6736(99)80040-3","volume":"354","author":"EA Simoes","year":"1999","unstructured":"Simoes EA (1999) Respiratory syncytial virus infection. Lancet 354(9181):847\u2013852","journal-title":"Lancet"},{"issue":"2","key":"3289_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.vaccine.2015.05.093","volume":"34","author":"K Modjarrad","year":"2016","unstructured":"Modjarrad K et al (2016) WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23\u201324 March 2015. Vaccine 34(2):190\u2013197","journal-title":"Vaccine"},{"issue":"suppl_1","key":"3289_CR24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1093\/infdis\/jiu828","volume":"211","author":"EA Sim\u00f5es","year":"2015","unstructured":"Sim\u00f5es EA et al (2015) Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis 211(suppl_1):S1\u2013S20","journal-title":"J Infect Dis"},{"key":"3289_CR25","doi-asserted-by":"publisher","first-page":"16271","DOI":"10.1038\/nmicrobiol.2016.271","volume":"2","author":"JJ Mousa","year":"2017","unstructured":"Mousa JJ et al (2017) A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein. Nat Microbiol 2:16271","journal-title":"Nat Microbiol"},{"issue":"8","key":"3289_CR26","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1073\/pnas.1115941109","volume":"109","author":"M Magro","year":"2012","unstructured":"Magro M et al (2012) Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci 109(8):3089\u20133094","journal-title":"Proc Natl Acad Sci"},{"issue":"309","key":"3289_CR27","doi-asserted-by":"publisher","first-page":"309ra162","DOI":"10.1126\/scitranslmed.aac4241","volume":"7","author":"JO Ngwuta","year":"2015","unstructured":"Ngwuta JO et al (2015) Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 7(309):309ra162\u2013309ra162","journal-title":"Sci Transl Med"},{"issue":"7","key":"3289_CR28","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/JVI.63.7.2941-2950.1989","volume":"63","author":"JA Beeler","year":"1989","unstructured":"Beeler JA, van Wyke Coelingh K (1989) Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63(7):2941\u20132950","journal-title":"J Virol"},{"issue":"6136","key":"3289_CR29","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1126\/science.1234914","volume":"340","author":"JS McLellan","year":"2013","unstructured":"McLellan JS et al (2013) Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340(6136):1113\u20131117","journal-title":"Science"},{"key":"3289_CR30","doi-asserted-by":"crossref","unstructured":"Krarup A et al (2015) A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun 6:8143","DOI":"10.1038\/ncomms9143"},{"key":"3289_CR31","doi-asserted-by":"publisher","unstructured":"Gilman MS et al (2016) Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol 1(6). https:\/\/doi.org\/10.1126\/sciimmunol.aaj1879","DOI":"10.1126\/sciimmunol.aaj1879"},{"issue":"26","key":"3289_CR32","doi-asserted-by":"publisher","first-page":"14172","DOI":"10.1073\/pnas.260499197","volume":"97","author":"X Zhao","year":"2000","unstructured":"Zhao X et al (2000) Structural characterization of the human respiratory syncytial virus fusion protein core. Proc Natl Acad Sci 97(26):14172\u201314177","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"3289_CR33","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/s41467-017-01858-w","volume":"8","author":"D Tian","year":"2017","unstructured":"Tian D et al (2017) Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nat Commun 8(1):1877","journal-title":"Nat Commun"},{"issue":"30","key":"3289_CR34","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1016\/j.vaccine.2016.04.083","volume":"34","author":"BS Graham","year":"2016","unstructured":"Graham BS (2016) Vaccines against respiratory syncytial virus: the time has finally come. Vaccine 34(30):3535\u20133541","journal-title":"Vaccine"},{"issue":"1","key":"3289_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.molimm.2014.12.004","volume":"66","author":"E Guzman","year":"2015","unstructured":"Guzman E, Taylor G (2015) Immunology of bovine respiratory syncytial virus in calves. Mol Immunol 66(1):48\u201356","journal-title":"Mol Immunol"},{"issue":"12","key":"3289_CR36","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1073\/pnas.82.12.4075","volume":"82","author":"GW Wertz","year":"1985","unstructured":"Wertz GW et al (1985) Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci 82(12):4075\u20134079","journal-title":"Proc Natl Acad Sci"},{"key":"3289_CR37","doi-asserted-by":"crossref","unstructured":"Openshaw PJ (2013) The mouse model of respiratory syncytial virus disease. Curr Top Microbiol Immunol 372:359\u2013369","DOI":"10.1007\/978-3-642-38919-1_18"},{"key":"3289_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.coviro.2016.01.003","volume":"16","author":"TJ Ruckwardt","year":"2016","unstructured":"Ruckwardt TJ, Morabito KM, Graham BS (2016) Determinants of early life immune responses to RSV infection. Curr Opin Virol 16:151\u2013157","journal-title":"Curr Opin Virol"},{"issue":"3","key":"3289_CR39","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.coviro.2012.01.008","volume":"2","author":"ER Watkiss","year":"2012","unstructured":"Watkiss ER (2012) Pathogenesis of respiratory syncytial virus. Curr Opin Virol 2(3):300\u2013305","journal-title":"Curr Opin Virol"},{"issue":"1","key":"3289_CR40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/modpathol.3800725","volume":"20","author":"JE Johnson","year":"2007","unstructured":"Johnson JE et al (2007) The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 20(1):108\u2013119","journal-title":"Mod Pathol"},{"issue":"13","key":"3289_CR41","doi-asserted-by":"publisher","first-page":"8651","DOI":"10.1128\/JVI.79.13.8651-8654.2005","volume":"79","author":"PF Wright","year":"2005","unstructured":"Wright PF et al (2005) Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract. J Virol 79(13):8651\u20138654","journal-title":"J Virol"},{"issue":"19","key":"3289_CR42","doi-asserted-by":"publisher","first-page":"10300","DOI":"10.1128\/JVI.05164-11","volume":"85","author":"W Wu","year":"2011","unstructured":"Wu W et al (2011) Characterization of the interaction between human respiratory syncytial virus and the cell cycle in continuous cell culture and primary human airway epithelial cells. J Virol 85(19):10300\u201310309","journal-title":"J Virol"},{"issue":"10","key":"3289_CR43","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1164\/rccm.201002-0221OC","volume":"182","author":"JP DeVincenzo","year":"2010","unstructured":"DeVincenzo JP et al (2010) Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 182(10):1305\u20131314","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"3289_CR44","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1128\/JVI.01853-08","volume":"83","author":"ML Moore","year":"2009","unstructured":"Moore ML et al (2009) A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol 83(9):4185\u20134194","journal-title":"J Virol"},{"issue":"12","key":"3289_CR45","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.1128\/JVI.01693-10","volume":"85","author":"KL Stokes","year":"2011","unstructured":"Stokes KL et al (2011) Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB\/c mice. J Virol 85(12):5782\u20135793","journal-title":"J Virol"},{"issue":"4","key":"3289_CR46","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1128\/JVI.01420-06","volume":"81","author":"V Bitko","year":"2007","unstructured":"Bitko V et al (2007) Nonstructural proteins of respiratory syncytial virus suppress premature apoptosis by an NF-\u03baB-dependent, interferon-independent mechanism and facilitate virus growth. J Virol 81(4):1786\u20131795","journal-title":"J Virol"},{"issue":"8","key":"3289_CR47","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/90675","volume":"2","author":"RA Tripp","year":"2001","unstructured":"Tripp RA et al (2001) CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2(8):732\u2013738","journal-title":"Nat Immunol"},{"issue":"24","key":"3289_CR48","doi-asserted-by":"publisher","first-page":"12191","DOI":"10.1128\/JVI.01604-08","volume":"82","author":"A Bukreyev","year":"2008","unstructured":"Bukreyev A et al (2008) The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol 82(24):12191\u201312204","journal-title":"J Virol"},{"issue":"25","key":"3289_CR49","doi-asserted-by":"publisher","first-page":"8996","DOI":"10.1073\/pnas.0409478102","volume":"102","author":"FP Polack","year":"2005","unstructured":"Polack FP et al (2005) The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc Natl Acad Sci U S A 102(25):8996\u20139001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3289_CR50","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1089\/vim.2007.0110","volume":"21","author":"NW Lukacs","year":"2008","unstructured":"Lukacs NW et al (2008) Regulation of immunity to respiratory syncytial virus by dendritic cells, toll-like receptors, and notch. Viral Immunol 21(2):115\u2013122","journal-title":"Viral Immunol"},{"issue":"5","key":"3289_CR51","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1128\/JVI.01625-07","volume":"82","author":"PL Collins","year":"2008","unstructured":"Collins PL, Graham BS (2008) Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 82(5):2040\u20132055","journal-title":"J Virol"},{"issue":"6","key":"3289_CR52","doi-asserted-by":"publisher","first-page":"e1513","DOI":"10.1542\/peds.2010-3054","volume":"127","author":"ME Belderbos","year":"2011","unstructured":"Belderbos ME et al (2011) Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis. Pediatrics 127(6):e1513\u2013e1520","journal-title":"Pediatrics"},{"issue":"4","key":"3289_CR53","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1128\/CMR.00017-08","volume":"21","author":"I Miyairi","year":"2008","unstructured":"Miyairi I, DeVincenzo JP (2008) Human genetic factors and respiratory syncytial virus disease severity. Clin Microbiol Rev 21(4):686\u2013703","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"3289_CR54","doi-asserted-by":"publisher","first-page":"e1004757","DOI":"10.1371\/journal.ppat.1004757","volume":"11","author":"CJ Knudson","year":"2015","unstructured":"Knudson CJ et al (2015) RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets. PLoS Pathog 11(3):e1004757","journal-title":"PLoS Pathog"},{"issue":"1","key":"3289_CR55","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/rmv.518","volume":"17","author":"SV Littel-van den Hurk","year":"2007","unstructured":"Littel-van den Hurk SV et al (2007) Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 17(1):5\u201334","journal-title":"Rev Med Virol"},{"issue":"3","key":"3289_CR56","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.envres.2008.11.006","volume":"109","author":"CJ Karr","year":"2009","unstructured":"Karr CJ et al (2009) Infant exposure to fine particulate matter and traffic and risk of hospitalization for RSV bronchiolitis in a region with lower ambient air pollution. Environ Res 109(3):321\u2013327","journal-title":"Environ Res"},{"issue":"1","key":"3289_CR57","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1542\/peds.2004-0059","volume":"115","author":"JP Bradley","year":"2005","unstructured":"Bradley JP et al (2005) Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy. Pediatrics 115(1):e7\u2013e14","journal-title":"Pediatrics"},{"issue":"2","key":"3289_CR58","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1165\/rcmb.2008-0131OC","volume":"41","author":"DJ Groskreutz","year":"2009","unstructured":"Groskreutz DJ et al (2009) Cigarette smoke alters respiratory syncytial virus\u2013induced apoptosis and replication. Am J Respir Cell Mol Biol 41(2):189\u2013198","journal-title":"Am J Respir Cell Mol Biol"},{"key":"3289_CR59","doi-asserted-by":"publisher","unstructured":"Evangelisti M et al (2015) Air pollution and bronchiolitis from 2004 to 2014 in Rome. Eur Respir J 46. https:\/\/doi.org\/10.1183\/13993003.congress-2015.PA4505","DOI":"10.1183\/13993003.congress-2015.PA4505"},{"key":"3289_CR60","first-page":"1","volume":"5","author":"AL Gervassi","year":"2014","unstructured":"Gervassi AL, Horton H (2014) Is infant immunity actively suppressed or immature? Virology 5:1","journal-title":"Virology"},{"issue":"6011","key":"3289_CR61","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1126\/science.1196509","volume":"330","author":"JE Mold","year":"2010","unstructured":"Mold JE et al (2010) Fetal and adult hematopoietic stem cells give rise to distinct T cell lineages in humans. Science 330(6011):1695\u20131699","journal-title":"Science"},{"key":"3289_CR62","doi-asserted-by":"crossref","unstructured":"Ndure J, Flanagan KL (2014) Targeting regulatory T cells to improve vaccine immunogenicity in early life. Front Microbiol 5:477","DOI":"10.3389\/fmicb.2014.00477"},{"issue":"7","key":"3289_CR63","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.it.2014.04.007","volume":"35","author":"DJ Dowling","year":"2014","unstructured":"Dowling DJ, Levy O (2014) Ontogeny of early life immunity. Trends Immunol 35(7):299\u2013310","journal-title":"Trends Immunol"},{"issue":"9","key":"3289_CR64","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1586\/1744666X.2014.942288","volume":"10","author":"S Basha","year":"2014","unstructured":"Basha S, Surendran N, Pichichero M (2014) Immune responses in neonates. Expert Rev Clin Immunol 10(9):1171\u20131184","journal-title":"Expert Rev Clin Immunol"},{"issue":"16","key":"3289_CR65","doi-asserted-by":"publisher","first-page":"9350","DOI":"10.1128\/JVI.00818-14","volume":"88","author":"SA Cormier","year":"2014","unstructured":"Cormier SA et al (2014) Limited type I interferons and plasmacytoid dendritic cells during neonatal respiratory syncytial virus infection permit immunopathogenesis upon reinfection. J Virol 88(16):9350\u20139360","journal-title":"J Virol"},{"issue":"2","key":"3289_CR66","doi-asserted-by":"publisher","first-page":"e1003934","DOI":"10.1371\/journal.ppat.1003934","volume":"10","author":"TJ Ruckwardt","year":"2014","unstructured":"Ruckwardt TJ et al (2014) Quantitative and qualitative deficits in neonatal lung-migratory dendritic cells impact the generation of the CD8+ T cell response. PLoS Pathog 10(2):e1003934","journal-title":"PLoS Pathog"},{"issue":"3","key":"3289_CR67","doi-asserted-by":"publisher","first-page":"948","DOI":"10.4049\/jimmunol.1302007","volume":"192","author":"N Marr","year":"2014","unstructured":"Marr N et al (2014) Attenuation of respiratory syncytial virus\u2013induced and RIG-I\u2013dependent type I IFN responses in human neonates and very young children. J Immunol 192(3):948\u2013957","journal-title":"J Immunol"},{"key":"3289_CR68","doi-asserted-by":"crossref","unstructured":"Malloy AM, Falsey AR, Ruckwardt TJ (2013) Consequences of immature and senescent immune responses for infection with respiratory syncytial virus. Curr Top Microbiol Immunol 372:211\u2013231","DOI":"10.1007\/978-3-642-38919-1_11"},{"issue":"4","key":"3289_CR69","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/ni.3123","volume":"16","author":"A Iwasaki","year":"2015","unstructured":"Iwasaki A, Medzhitov R (2015) Control of adaptive immunity by the innate immune system. Nat Immunol 16(4):343\u2013353","journal-title":"Nat Immunol"},{"key":"3289_CR70","doi-asserted-by":"crossref","unstructured":"Lambert L et al (2014) Immunity to RSV in early-life. Front Immunol 5:466","DOI":"10.3389\/fimmu.2014.00466"},{"key":"3289_CR71","doi-asserted-by":"crossref","unstructured":"Karron RA, Buchholz UJ, Collins PL (2013) Live-attenuated respiratory syncytial virus vaccines. In: Anderson L, Graham B (eds) Challenges and opportunities for respiratory syncytial virus vaccines. Current Topics in Microbiology and Immunology, vol 372. Springer, Berlin, Heidelberg","DOI":"10.1007\/978-3-642-38919-1_13"},{"issue":"3","key":"3289_CR72","doi-asserted-by":"publisher","first-page":"e1005486","DOI":"10.1371\/journal.ppat.1005486","volume":"12","author":"J Liu","year":"2016","unstructured":"Liu J et al (2016) A numerically subdominant CD8 T cell response to matrix protein of respiratory syncytial virus controls infection with limited immunopathology. PLoS Pathog 12(3):e1005486","journal-title":"PLoS Pathog"},{"issue":"2","key":"3289_CR73","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/mi.2016.48","volume":"10","author":"KM Morabito","year":"2017","unstructured":"Morabito KM et al (2017) Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung. Mucosal Immunol 10(2):545\u2013554","journal-title":"Mucosal Immunol"},{"issue":"8","key":"3289_CR74","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1086\/512615","volume":"195","author":"TP Welliver","year":"2007","unstructured":"Welliver TP et al (2007) Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 195(8):1126\u20131136","journal-title":"J Infect Dis"},{"issue":"4","key":"3289_CR75","first-page":"463","volume":"95","author":"JR Groothuis","year":"1995","unstructured":"Groothuis JR et al (1995) Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics 95(4):463\u2013467","journal-title":"Pediatrics"},{"issue":"3","key":"3289_CR76","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nri2508","volume":"9","author":"R., S.C.a.A","year":"2009","unstructured":"R., S.C.a.A (2009) B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 9(3):185\u2013194","journal-title":"Nat Rev Immunol"},{"issue":"37","key":"3289_CR77","doi-asserted-by":"publisher","first-page":"4726","DOI":"10.1016\/j.vaccine.2014.05.038","volume":"32","author":"CJ Sande","year":"2014","unstructured":"Sande CJ, Cane PA, Nokes DJ (2014) The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants. Vaccine 32(37):4726\u20134729","journal-title":"Vaccine"},{"issue":"11","key":"3289_CR78","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.1128\/JVI.76.11.5654-5666.2002","volume":"76","author":"L Zhang","year":"2002","unstructured":"Zhang L et al (2002) Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 76(11):5654\u20135666","journal-title":"J Virol"},{"issue":"6","key":"3289_CR79","first-page":"647","volume":"45","author":"M Hambling","year":"1964","unstructured":"Hambling M (1964) Survival of the respiratory syncytial virus during storage under various conditions. Br J Exp Pathol 45(6):647","journal-title":"Br J Exp Pathol"},{"key":"3289_CR80","doi-asserted-by":"publisher","first-page":"34108","DOI":"10.1038\/srep34108","volume":"6","author":"AM Killikelly","year":"2016","unstructured":"Killikelly AM, Kanekiyo M, Graham BS (2016) Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. Sci Rep 6:34108","journal-title":"Sci Rep"},{"issue":"3","key":"3289_CR81","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1128\/JVI.06096-11","volume":"86","author":"TR Johnson","year":"2012","unstructured":"Johnson TR, McLellan JS, Graham BS (2012) Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2. J Virol 86(3):1339\u20131347","journal-title":"J Virol"},{"issue":"3","key":"3289_CR82","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3181\/00379727-92-22538","volume":"92","author":"J Morris","year":"1956","unstructured":"Morris J, Blount R Jr, Savage R (1956) Recovery of cytopathogenic agent from chimpanzees with goryza. Proc Soc Exp Biol Med 92(3):544\u2013549","journal-title":"Proc Soc Exp Biol Med"},{"issue":"4","key":"3289_CR83","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","volume":"89","author":"HW KIM","year":"1969","unstructured":"KIM HW et al (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine 1 2. Am J Epidemiol 89(4):422\u2013434","journal-title":"Am J Epidemiol"},{"issue":"8","key":"3289_CR84","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/JCM.26.8.1595-1597.1988","volume":"26","author":"BR Murphy","year":"1988","unstructured":"Murphy BR, Walsh EE (1988) Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 26(8):1595\u20131597","journal-title":"J Clin Microbiol"},{"issue":"47","key":"3289_CR85","doi-asserted-by":"publisher","first-page":"6473","DOI":"10.1016\/j.vaccine.2015.06.119","volume":"33","author":"FP Polack","year":"2015","unstructured":"Polack FP (2015) The changing landscape of respiratory syncytial virus. Vaccine 33(47):6473\u20136478","journal-title":"Vaccine"},{"issue":"6158","key":"3289_CR86","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","volume":"342","author":"JS McLellan","year":"2013","unstructured":"McLellan JS et al (2013) Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342(6158):592\u2013598","journal-title":"Science"},{"issue":"8","key":"3289_CR87","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nm1456","volume":"12","author":"A Moghaddam","year":"2006","unstructured":"Moghaddam A et al (2006) A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 12(8):905\u2013907","journal-title":"Nat Med"},{"issue":"Supplement_1","key":"3289_CR88","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1093\/infdis\/171.Supplement_1.S44","volume":"171","author":"R Clemens","year":"1995","unstructured":"Clemens R et al (1995) Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 171(Supplement_1):S44\u2013S49","journal-title":"J Infect Dis"},{"issue":"3","key":"3289_CR89","first-page":"343","volume":"152","author":"J Furesz","year":"1995","unstructured":"Furesz J, Scheifele DW, Palkonyay L (1995) Safety and effectiveness of the new inactivated hepatitis A virus vaccine. CMAJ 152(3):343","journal-title":"CMAJ"},{"key":"3289_CR90","doi-asserted-by":"publisher","unstructured":"Zhao M et al (2017) Discovery of a prefusion RSV F-specific monoclonal antibody that provides greater in vivo protection than the murine precursor of Palivizumab. J Virol 91(15). https:\/\/doi.org\/10.1128\/JVI.00176-17","DOI":"10.1128\/JVI.00176-17"},{"issue":"7","key":"3289_CR91","doi-asserted-by":"publisher","first-page":"e1005035","DOI":"10.1371\/journal.ppat.1005035","volume":"11","author":"MS Gilman","year":"2015","unstructured":"Gilman MS et al (2015) Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS Pathog 11(7):e1005035","journal-title":"PLoS Pathog"},{"key":"3289_CR92","doi-asserted-by":"publisher","first-page":"B209","DOI":"10.1016\/j.vaccine.2012.11.106","volume":"31","author":"L Anderson","year":"2013","unstructured":"Anderson L et al (2013) Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 31:B209\u2013B215","journal-title":"Vaccine"},{"issue":"9","key":"3289_CR93","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/infdis\/jiy066","volume":"217","author":"UJ Buchholz","year":"2018","unstructured":"Buchholz UJ et al (2018) Live respiratory syncytial virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children. J Infect Dis 217(9):1338\u20131346","journal-title":"J Infect Dis"},{"key":"3289_CR94","doi-asserted-by":"crossref","unstructured":"Shah RR, Hassett KJ, Brito LA (2017) Overview of vaccine adjuvants: introduction, history, and current status. Methods Mol Biol 1494:1\u201313","DOI":"10.1007\/978-1-4939-6445-1_1"},{"issue":"10","key":"3289_CR95","doi-asserted-by":"publisher","first-page":"e0186854","DOI":"10.1371\/journal.pone.0186854","volume":"12","author":"M Sastry","year":"2017","unstructured":"Sastry M et al (2017) Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus. PLoS One 12(10):e0186854","journal-title":"PLoS One"},{"issue":"25","key":"3289_CR96","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1016\/j.vaccine.2016.04.002","volume":"34","author":"J Falloon","year":"2016","unstructured":"Falloon J et al (2016) A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant. Vaccine 34(25):2847\u20132854","journal-title":"Vaccine"},{"issue":"300","key":"3289_CR97","doi-asserted-by":"publisher","first-page":"300ra127","DOI":"10.1126\/scitranslmed.aac5757","volume":"7","author":"G Taylor","year":"2015","unstructured":"Taylor G et al (2015) Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections. Sci Transl Med 7(300):300ra127\u2013300ra127","journal-title":"Sci Transl Med"},{"key":"3289_CR98","doi-asserted-by":"crossref","unstructured":"Pardi N, Weissman D (2017) Nucleoside modified mRNA vaccines for infectious diseases. Methods Mol Biol 1499:109\u2013121","DOI":"10.1007\/978-1-4939-6481-9_6"},{"issue":"22","key":"3289_CR99","doi-asserted-by":"publisher","first-page":"e01101-17","DOI":"10.1128\/JVI.01101-17","volume":"91","author":"X Liu","year":"2017","unstructured":"Liu X et al (2017) Attenuated human parainfluenza virus type 1 expressing the respiratory syncytial virus (RSV) fusion (F) glycoprotein from an added gene: effects of prefusion stabilization and packaging of RSV F. J Virol 91(22):e01101-17","journal-title":"J Virol"},{"key":"3289_CR100","doi-asserted-by":"publisher","unstructured":"Liang B et al (2017) Improved prefusion stability, optimized codon-usage, and augmented virion packaging enhance the immunogenicity of respiratory syncytial virus (RSV) fusion protein in a vectored vaccine candidate. J Virol 91(15). https:\/\/doi.org\/10.1128\/JVI.00189-17","DOI":"10.1128\/JVI.00189-17"},{"key":"3289_CR101","unstructured":"Novavax.\u00a0A study to determine the safety and efficacy of the RSV F vaccine to protect infants via maternal immunization. @ NIH clinical trial: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02624947"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-018-3289-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-018-3289-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-018-3289-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T23:25:04Z","timestamp":1604359504000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-018-3289-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,6]]},"references-count":101,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["3289"],"URL":"https:\/\/doi.org\/10.1007\/s10096-018-3289-4","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,6]]},"assertion":[{"value":"7 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"N\/A","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"N\/A","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}